Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$21 Mln
P/E Ratio
--
P/B Ratio
1.66
Industry P/E
--
Debt to Equity
0.99
ROE
-3.88 %
ROCE
-112.76 %
Div. Yield
0 %
Book Value
3.08
EPS
-9.63
CFO
$-544.50 Mln
EBITDA
$-559.34 Mln
Net Profit
$-586.87 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Kala Pharmaceuticals (KALA)
| -54.18 | -53.64 | -60.79 | -50.31 | -56.05 | -63.17 | -- |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Kala Pharmaceuticals (KALA)
| -0.85 | -81.65 | 26.12 | -82.15 | 83.74 | -24.54 | -73.36 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 6,904.81 | -- | 38.11 | |
| 71.71 | 7,574.08 | 58.3 | 23.56 | |
| 59.16 | 11,448.88 | 394.4 | 0.76 | |
| 8.13 | 9,704.70 | -- | -3.24 |
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012,... which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts. Read more
Chairman & CEO
Mr. Mark T. Iwicki
Chairman & CEO
Mr. Mark T. Iwicki
Headquarters
Arlington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kala Pharmaceuticals Inc (KALA) stood at $ 55 Mln as on 31-Dec-24
The share price of Kala Pharmaceuticals Inc (KALA) is $3.18 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Kala Pharmaceuticals Inc (KALA) has given a return of -56.05% in the last 3 years.
Kala Pharmaceuticals Inc (KALA) has a market capitalisation of $ 21 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Kala Pharmaceuticals Inc (KALA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kala Pharmaceuticals Inc (KALA) and enter the required number of quantities and click on buy to purchase the shares of Kala Pharmaceuticals Inc (KALA).
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
The CEO & director of Mr. Mark T. Iwicki. is Kala Pharmaceuticals Inc (KALA), and CFO & Sr. VP is Mr. Mark T. Iwicki.
There is no promoter pledging in Kala Pharmaceuticals Inc (KALA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,122
|
|
|
932
|
|
|
731
|
|
|
670
|
| Kala Pharmaceuticals Inc. (KALA) | Ratios |
|---|---|
|
Return on equity(%)
|
-388.29
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Kala Pharmaceuticals Inc (KALA) was $0 Mln.
$-0.12
(
